In light of this, a Mendelian randomization (MR) study was required to explore whether SGLT2 inhibition was significantly linked to the risk of cardiac events-induced death via the mediation of venous thrombosis at a genetic level. Here, SLC5A2 is linked to Venous thrombosis.